What FORT does

FORT (OOO FORT) is a Russian full-cycle biopharmaceutical manufacturer, legally incorporated in 2006 with production operations commencing in 2014, headquartered at a 39,800 m² scientific and production complex in Yaltunovo, Ryazan Oblast. It is the largest influenza vaccine manufacturer in Russia, with annual production capacity of up to 40 million doses and a record output of 35.6 million doses in 2022. The company is a wholly-owned subsidiary of Nacimbio holding, which in turn is controlled by Rostec State Corporation, and operates as a state strategic asset within the Russian pharmaceutical sovereignty framework.

FORT produces two core influenza vaccines: Ultriks Kvadri, a quadrivalent inactivated split vaccine launched in 2019 and included in Russia's National Preventive Vaccination Schedule (NKPP) since launch, containing 15 mcg hemagglutinin of each of four WHO-recommended strains (60 mcg total) without preservatives or adjuvants; and Sovigripp, a trivalent inactivated subunit vaccine with the proprietary Sovidon adjuvant. Both products are manufactured through complete in-house production cycles from antigen development to finished pharmaceutical form, compliant with international GMP standards. Quality control accounts for 70% of total production time, and 14.1 million Ultriks Kvadri doses were delivered for the 2024-2025 season out of 70.6 million total Nacimbio influenza vaccine deliveries. The company also operates a pharmacovigilance service for adverse reaction monitoring.

FORT operates exclusively as a B2G (business-to-government) supplier, generating revenue through Russian National Immunization Calendar contracts, direct procurement contracts with regional governments, and international export to government health ministries in Turkmenistan, Belarus, and Kazakhstan. Pricing is not publicly disclosed because transactions occur through state procurement. A 3 billion ruble investment project signed in 2021 between Nacimbio and the Ryazan Oblast government is doubling production capacity over three years. The company employs 600+ people and maintains long-term educational partnerships with three Ryazan-region universities for talent development.

Name

FORT

Legal name

OOO FORT (ООО «ФОРТ»)

Website

https://fort-bt.ru

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

FORT is the largest influenza vaccine manufacturer in Russia, a state-owned biopharma company producing full-cycle quadrivalent and trivalent influenza vaccines for the National Immunization Calendar and export to CIS countries. It operates as a Nacimbio/Rostec subsidiary from its Ryazan Oblast facility with 40 million dose capacity.

Ownership category

akta.pro rank

Product category

Influenza Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Manufacturing & Fill-Finish (HLAIAEAJ)

akta.pro secondary industries

Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD), Vaccine Combination Products (Multivalent/Co-formulated) (HLAIAEAO), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

Keywords

• Influenza vaccine manufacturing
• Biopharmaceutical production
• Immunobiological medicines
• Quadrivalent influenza vaccines
• Vaccine contract manufacturing

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Government Vaccine Supply: Supply of influenza vaccines to Russian healthcare system through National Immunization Calendar contracts and direct procurement contracts with regional governments.
2. International Export: Export of influenza vaccines to international markets including Turkmenistan, Belarus, and Kazakhstan, with expansion plans.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

FORT manufactures and supplies influenza vaccines for Russia's National Immunization Calendar and international government health programs. Its two core products are the quadrivalent inactivated split vaccine Ультрикс® Квадри (Ultrix Quadri) and the trivalent inactivated subunit vaccine Совигрипп® (Sovigripp). The company operates a full-cycle biopharmaceutical production facility in Ryazan Oblast with capacity of up to 40 million doses per year, supplying government healthcare institutions domestically and abroad.

Product overview

FORT is a full-cycle biopharmaceutical company — the largest influenza vaccine manufacturer in Russia — producing immunobiological medicinal products at its facility in Ryazan Oblast. Its product portfolio consists of two core influenza vaccines: Ультрикс® Квадри, a quadrivalent (four-valent) inactivated split vaccine launched in 2019, and Совигрипп®, a trivalent inactivated subunit vaccine with adjuvant. Both products are manufactured from domestically produced antigens through complete production cycles compliant with international GMP standards, and are supplied under Russia's National Immunization Schedule. The company also operates a pharmacovigilance (фармаконадзор) service to monitor product safety.

Differentiator

Problem solved

Functional benefit

Brands

• Ультрикс® Квадри (Ultriks Kvadri): Four-valent inactivated split influenza vaccine containing 15 mcg of hemagglutinin of each of four influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria), total 60 mcg per dose. No preservatives or adjuvants. Included in Russia's National Preventive Vaccination Schedule since 2019. Approved for all ages including children from 6 months and pregnant women.
• Совигрипп® (Sovigripp)

Products and services

• Ультрикс® Квадри (Ultrix Quadri) Quadrivalent inactivated split influenza vaccine containing 60 mcg of hemagglutinin (15 mcg each of four strains: A/H1N1, A/H3N2, B/Yamagata, B/Victoria). The first Russian four-valent influenza vaccine of full production cycle, developed in accordance with WHO recommendations. Contains no preservatives or adjuvants. Approved for use in adults, children from 6 months, and pregnant women. Supplied through Russia's National Immunization Calendar and exported to CIS countries.
• Совигрипп® (Sovigripp) Trivalent inactivated subunit influenza vaccine with adjuvant Sovidon. Contains hemagglutinin of two influenza A subtypes (H1N1 and H3N2, 5 mcg each) and one influenza B strain (11 mcg). Available with or without preservative (thimerosal). Approved for children from 6 months, adults without age limit, and pregnant women (preservative-free version). Manufactured at the FORT facility using proprietary antigen.
• Фармаконадзор (Pharmacovigilance Service) Pharmacovigilance system operating in accordance with international standards and Russian regulatory requirements to ensure monitoring of safety and efficacy of FORT's medicinal products. Provides adverse reaction reporting forms for patients and healthcare professionals.

Quantifiable outcome

• Risk of influenza infection is 86 times lower among vaccinated individuals (NASCI research, 2024)
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Pharmaceutical Cluster of Ryazan OblastcoreStrategic or Co-development Partner · 13 June 2023FORT joined the pharmaceutical cluster of Ryazan Oblast, which functions since 2021 with 14 participants including 3 educational organizations. Cluster aims to develop cooperative relations for new drug development, research, quality improvement, and export expansion.
• Government of Ryazan OblastcoreStrategic or Co-development Partner · 3 June 2021Joint investment agreement signed at St. Petersburg International Economic Forum for doubling influenza vaccine production capacity over 3 years. Regional government supports high-tech manufacturing development and employment in the region.
• Nacimbio (Нацимбио)coreStrategic or Co-development PartnerFORT is a subsidiary of Nacimbio holding within Rostec State Corporation. Nacimbio coordinates strategic development, investment projects, and integration into national immunization programs. Nacimbio CEO Andrey Zagosrky leads joint expansion initiatives.
• Rostec State Corporation (Госкорпорация Ростех)coreStrategic or Co-development PartnerFORT operates as part of Rostec's Nacimbio holding. Rostec provides state support for development, financing, and strategic direction. The corporation backs major investment projects including the 3 billion ruble capacity expansion.
• Ryazan State Medical University (Рязанский медицинский университет)minorStrategic or Co-development PartnerLong-term partnership for student internships, practical training, and graduate employment. University students conduct internships in microbiological, virological, physico-chemical laboratories and production departments.
• Ryazan State UniversityminorStrategic or Co-development PartnerPartnership for employing graduates in biotechnology and bioengineering fields. Annual recruitment of graduates from relevant specializations.
• Ryazan State Agrotechnological UniversityminorStrategic or Co-development PartnerEducational partnership for student internships and graduate employment in biotechnology and related fields.
• Vector (Вектор) - State Scientific CentercoreStrategic or Co-development PartnerVector (State Research Center of Virology and Biotechnology, Rospotrebnadzor) conducts independent evaluation and testing of Russian influenza vaccines, providing scientific validation of FORT's products.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• GC Biopharma (formerly Green Cross): South Korean biopharmaceutical company with established quadrivalent influenza vaccine products. Comparable in product offering and quality certifications, serving as a regional competitor in Asian markets.
• Bharat Biotech: Indian vaccine manufacturer with broad portfolio including influenza and emerging-market distribution focus. Comparable in scale and emerging-market export orientation, though more diversified across indications.

Broad incumbents

• CSL Seqirus: One of the world's largest influenza vaccine manufacturers, producing both inactivated and adjuvanted flu vaccines. A direct global comparable to FORT's Sovigripp and Ultriks Kvadri product categories.
• Sanofi: Global vaccine leader with influenza franchises (Fluzone, Vaxigrip). Sets the international benchmark for quadrivalent vaccine technology and competes with FORT's Ultriks Kvadri in markets where Russian-made vaccines are accepted.
• GSK: Major global vaccine manufacturer with a significant influenza portfolio. Comparable in full-cycle biomanufacturing capabilities and serves as a benchmark for the scale and rigor of FORT's quality systems.
• Nacimbio (parent company holdings): Rostec-owned pharmaceutical holding that bundles FORT with other vaccine manufacturers. As the immediate parent, it provides strategic coordination and NKPP contract management that FORT depends on.

Direct peers

• Petrovax: Russian pharmaceutical company producing influenza vaccines and other immunobiological products. Competes with FORT in the Russian domestic vaccine market and is also part of the broader Russian pharma sovereignty initiative.
• Sinovac Biotech: Chinese biopharmaceutical company producing vaccines including influenza, with significant emerging-market export presence. Comparable in its focus on inactivated vaccine technology and emerging-market distribution.
• NPO Microgen: Russian state-owned immunobiological manufacturer producing influenza and other vaccines domestically. Operates under similar regulatory and procurement dynamics as FORT, competing for National Immunization Calendar volumes.
• Hualan Biological Engineering: China's largest influenza vaccine producer, manufacturing both trivalent and quadrivalent inactivated flu vaccines. Comparable to FORT in scale (hundreds of millions of doses), product profile, and government-driven demand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Fortbt
• Facebookfacebook.com/Fortbt

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FORT